Literature DB >> 27873660

Carbapenem-resistant Klebsiella pneumoniae infections in a Greek intensive care unit: Molecular characterisation and treatment challenges.

Maria Katsiari1, Giakkoupi Panagiota2, Sophia Likousi3, Zoi Roussou3, Michalis Polemis4, C Alkiviadis Vatopoulos5, D Evangelia Platsouka3, Asimina Maguina6.   

Abstract

Acquisition of carbapenemase-producing Klebsiella pneumoniae (CP-Kp) strains poses a major threat to critically ill patients. The objectives of this study were to describe the epidemiology of CP-Kp isolates as well as the clinical outcome associated with the corresponding infections and to identify risk factors for mortality of intensive care unit (ICU) patients in a Greek hospital. A prospective, observational study was conducted in a nine-bed general ICU over a 2-year period (April 2010-March 2012). Imipenem-resistant K. pneumoniae isolates recovered from clinical samples of ICU patients were prospectively collected and studied for the presence of carbapenemases. Isolates were submitted to molecular typing using pulsed-field gel electrophoresis (PFGE). In total, 61 CP-Kp isolates (48 KPC-producers and 13 VIM-producers) were recovered from 58 ICU patients. The majority of KPC-producers were classified into a single PFGE type, indicating potent clonal dissemination. Among the 32 infected patients, bacteraemia was diagnosed in 16. Tigecycline+colistin was the most common combination antimicrobial regimen. Infection-attributable mortality was 43.8%. Regarding mortality risk factors, non-survivors were older (P=0.080), all of them presented with septic shock (P=0.010) and they had higher Sepsis-related Organ Failure Assessment (SOFA) scores at infection onset (P=0.004) compared with survivors. Appropriate definitive treatment and combination regimens were not associated with patient survival. In conclusion, CP-Kp infections are associated with limited treatment options and high in-hospital mortality. Effective measures for preventing dissemination of respective isolates in the hospital setting are required. Copyright Â
© 2015 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carbapenemase-producing Klebsiella pneumoniae; Infection control bundle; Molecular typing; Mortality; Treatment regimens

Year:  2015        PMID: 27873660     DOI: 10.1016/j.jgar.2015.01.006

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  5 in total

Review 1.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 2.  Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae.

Authors:  Liangfei Xu; Xiaoxi Sun; Xiaoling Ma
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-03-29       Impact factor: 3.944

3.  Triple Versus Double Therapy for the Treatment of Severe Infections Caused by Carbapenem-Resistant Enterobacteriaceae: A Systematic Review and Meta-Analysis.

Authors:  Lei Wang; Xiang Tong; Jizhen Huang; Li Zhang; Dongguang Wang; Man Wu; Tao Liu; Hong Fan
Journal:  Front Pharmacol       Date:  2020-01-30       Impact factor: 5.810

4.  Polyclonal Endemicity of Carbapenemase-Producing Klebsiella pneumoniae in ICUs of a Greek Tertiary Care Hospital.

Authors:  Efthymia Protonotariou; Georgios Meletis; Dimitrios Pilalas; Paraskevi Mantzana; Areti Tychala; Charalampos Kotzamanidis; Dimitra Papadopoulou; Theofilos Papadopoulos; Michalis Polemis; Simeon Metallidis; Lemonia Skoura
Journal:  Antibiotics (Basel)       Date:  2022-01-25

5.  Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: Systematic Review and Meta-Analysis.

Authors:  Adrian Schmid; Aline Wolfensberger; Johannes Nemeth; Peter W Schreiber; Hugo Sax; Stefan P Kuster
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.